ASCO GU 2026 Analyst Briefing: Webinar
Executive Summary: ONCrg analyst Sarah Lockheed previews four late-breaking phase 3 readouts at ASCO GU 2026 covering the post-CPI RCC setting, adjuvant RCC, and perioperative and advanced bladder cancer — all centered on belzutifan combinations and the continued expansion of the enfortumab vedotin plus pembrolizumab franchise.